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Background: Recently, we demonstrated the beneficial effects of engineered heart tis-
sues for the treatment of dilated cardiomyopathy in rats. For further development of this
technique we started to produce engineered tissue (ET) from mesenchymal stem cells.
Interestingly, we observed a malignant tumor invading the heart with an inverse relation-
ship between proliferation markers and connexin expression.
Methods: Commercial CD54+/CD90+/CD34−/CD45− bone marrow derived mesenchymal
rat stem cells (cBM-MSC), characterized were used for production of mesenchymal stem-
cell-ET (MSC-ET) by suspending them in a collagen I, matrigel-mixture and cultivating for
14 days with electrical stimulation.Three MSC-ET were implanted around the beating heart
of adult rats for days. Another three MSC-ET were produced from freshly isolated rat bone
marrow derived stem cells (sBM-MSC).
Results:Three weeks after implantation of the MSC-ETs the hearts were surgically excised.
While in 5/6 cases the ET was clearly distinguishable and was found as a ring containing
mostly connective tissue around the heart, in 1/6 the heart was completely surrounded
by a huge, undifferentiated, pleomorphic tumor originating from the cMSC-ET (cBM-MSC),
classified as a high grade malignant sarcoma. Quantitatively we found a clear inverse rela-
tionship between cardiac connexin expression (Cx43, Cx40, or Cx45) and increased Ki-67
expression (Cx43: p< 0.0001, Cx45: p<0.03, Cx40: p<0.014). At the tumor-heart border
there were significantly more Ki-67 positive cells (p=0.001), and only 2% Cx45 and Ki-67-
expressing cells, while the other connexins were nearly completely absent (p<0.0001).
Conclusion and Hypothesis: These observations strongly suggest the hypothesis, that
invasive tumor growth is accompanied by reduction in connexins. This implicates that gap
junction communication between tumor and normal tissue is reduced or absent, which
could mean that growth and differentiation signals can not be exchanged.
Keywords: connexins, gap junctions, sarcoma, proliferation, tumour, Cx43, Cx40, Cx45
INTRODUCTION
There is a long standing debate about factors that may be involved
in the invasive growth of tumors. Among these gap junctions
have been discussed since Werner Loewenstein proposed that gap
junction intercellular communication (GJIC) might play a role in
tumorigenesis and that reduced communication may account for
loss of growth inhibition (Loewenstein and Kanno, 1966; Loewen-
stein, 1980). Since that time a number of papers has shown that in
primary tumors or tumor cell lines connexins can be downregu-
lated or even be absent, that oncogenes or cancerogenic drugs often
inhibit gap junction channel function or reduce connexin expres-
sion (Loewenstein and Kanno, 1966; Trosko et al., 1990; Lampe,
1994; Laird et al., 1999; Mesnil et al., 2005; Salameh and Dhein,
2005; Cronier et al., 2009). However, on the other hand, some
researchers found a role of gap junctions promoting invasion, cell
extravasation, and migration of tumor cells (Naoi et al., 2007;
Saito-Katsuragi et al., 2007; Ezumi et al., 2008), while others do not
support this view (Yano et al., 2006; Sato et al., 2008). This lead to
the interpretation that connexins might be“differentially regulated
during the dissemination of specific tumor types”(Naus and Laird,
2010), and that down-regulation of connexin in early tumors
might be linked to invasion, but in later states elevation in connex-
ins can occur facilitating extravasation and formation of secondary
tumors (Naus and Laird, 2010). Regarding tumor cells, GJIC may
exist among normal or (pre-)cancerous cells (homologous GJIC)
or between normal and (pre)cancerous cells (heterologous GJIC),
(Yamasaki et al., 1995), or may be absent. Thus, an open ques-
tion is, whether there are gap junctions at the border between a
tumor and the neighboring tissue. Another issue of debate is the
role of connexins in stem cells (Trosko et al., 2004). In recent
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years, mesenchymal stem cells (MSC) gained huge interest in
regenerative medicine and tissue engineering. To their exceptional
advantages belongs their multipotent differentiation capacity to
cell lineages, including myocytes, osteocytes, chondrocytes, teno-
cytes, and adipocytes (Pittenger et al., 1999). Additionally, MSC
can be derived from different tissues, like bone marrow (BM), adi-
pose tissue, and umbilical cord (Zuk et al., 2001; Romanov et al.,
2003). Until today, MSC, mostly BM-MSC, have been successfully
transplanted in animal models as well as in human patients suffer-
ing from for instance myocardial infarction, dilated cardiomyopa-
thy, stroke, neuroimmunological, and neurodegenerative diseases
(Horwitz et al., 1999; Bang et al., 2005; Nagaya et al., 2005; Karussis
et al., 2008; Tang et al., 2009; Chin et al., 2010). Furthermore MSC
have kept entering tumor research. Several in vivo and in vitro
studies have shown the ability of MSC to inhibit tumor growth
in different malignancies (Maestroni et al., 1999; Ohlsson et al.,
2003; Nakamura et al., 2004; Khakoo et al., 2006; Tian et al., 2010).
In contrast, various scientific groups observed, that MSC could
promote metastasis (Karnoub et al., 2007) and enhance tumor
growth (Gunn et al., 2006; Zhu et al., 2006; Spaeth et al., 2009),
which is assumed to be attributable to for instance immunosup-
pression (Djouad et al., 2003) or drug resistance (Kurtova et al.,
2009). Moreover several types of MSC may transform to malig-
nant cells in vitro and in vivo (Rubio et al., 2005; Miura et al., 2006;
Zhou et al., 2006; Tolar et al., 2007). Due to these contradictory
observations, Wong (2011) discussed in her paper the question,
whether MSC are “angels or demons.”
A kicking point about the role of a cell within a given tissue is
the question, whether this cell can communicate with its neigh-
boring cells, which may regulate growth and differentiation of the
cell via gap junctional intercellular communication (Loewenstein,
1980; Trosko et al., 1990). In that context, an even older stand-
ing debate than the scientific efforts in mesenchymal stem cells is
the questions about the role of connexins in tumor growth and
communicating with its surrounding. Gap Junction channels are
made from two hemichannels (connexons) contributed by either
of the neighboring cells. A connexon consists of 6 connexins, 4-
transmembrane spanning proteins, with an intracellular N- and
C-terminal. Twenty-one connexin isoforms are presently known,
which – besides other properties – differ in their molecular weight,
their gating properties, and their tissue distribution (Evans and
Martin, 2002; Söhl and Willecke, 2004).
Another open question in current regenerative medicine, in
particular cardiovascular approaches to BM-MSC therapy by BM-
MSC injection, is whether adult BM-MSC can form malignant
tumors or not, and whether in such a case these cells may com-
municate with normal tissue. In favor of this idea Valiunas et al.
(2004) showed in commercially available human MSC that these
cells can express Cx43, Cx40, and Cx45, and found punctuate Cx43
and Cx40 staining in regions of close cell–cell contact, while Cx45
was mostly found cytoplasmically. In addition, they showed that
these cells formed functional gap junction channels within their
population and with transfected HeLa cells.
In an investigation, which originally was aimed to investigate
the possible use of BM-MSC for cardiac tissue replacement ther-
apy by using these cells to form engineered heart tissue instead
of neonatal rat cardiomyocytes, which have been previously used
(Zimmermann et al., 2006; Leontyev et al., 2013) we observed
tumor formation in mesenchymal stem-cell-engineered tissue
(MSC-ET) after transplantation in vivo, and found characteristic
gap junction protein distributions.
The primary idea behind our study was to replace cardiomy-
ocytes in engineered heart tissue (Leontyev et al., 2013) by mes-
enchymal stem cells. To our surprise we observed a malignant
tumor originating from the ET. This tumor showed an interesting
reverse relationship between proliferation and expression of the
cardiac connexins Cx43, Cx40, and Cx45. Thus, those areas where
the tumor invaded the heart, were negative for cardiac connexins
but positive for Ki-67. In contrast – areas in the middle of the
tumor were negative for the proliferation marker Ki-67 but posi-
tive for connexins. Thus, this tumor exhibits both Cx-positive and
-negative areas.
MATERIALS AND METHODS
USED MSC LINES
We used two types of BM-MSC: (a) isolated by ourselves (sBM-
MSC; see below) and (b) a commercial rat BM-MSC (cBM-MSC)
from Gibco (S1601-100; Gibco, Darmstadt, Germany).
BM-MSC ISOLATION
For the isolation of sBM-MSC we used male Sprague Dawley rats
weighing about 250–350 g. The rats were anesthetized with: fen-
tanyl (0.005 mg/kg), midazolamhydrochloride (2 mg/kg), medeto-
midinehydrochloride (0.15 mg/kg), and ketamine (75 mg/kg).
Afterward the rats were killed by excising the heart. The femora
and tibias were dissected aseptically and washed with PBS. The
bone epiphyses were cut off and each remaining diaphysis was
placed in one pipette tip, which then was put in a Falcon tube. In
order to get the bone marrow out of the cavities we centrifuged
the bones (200× g, 5 min, 21˚C) (Dobson et al., 1999). The cell
pellets were purified from tissue remnants by a 100µm2-filter and
seeded on 75 mm2-flasks (one pellet per flask).
MSC CULTURE
Both cell lines were cultured at 5% CO2 and 37˚C in Dulbecco
modified Eagle medium-low glucose supplemented with 10% fetal
bovine serum and 2.5% Streptomycin/Penicillin. The first medium
change was performed after 3 days to remove the non-adherent
cells (Strawn et al., 2004). Afterward the medium was removed
every 3–4 days. When the MSC reached 80% confluence, they were
trypsinized and plated at a density between 2 and 6× 103/cm2.
CHARACTERIZATION OF MSC: FLOW CYTOMETRY AND ADIPOGENIC
DIFFERENTIATION
For characterization we performed flow cytometry and adi-
pogenic differentiation for three cultures of sBM-MSC (pas-
sage 3). For cBM-MSC (passage 6) we could validate the man-
ufacturer’s descriptions (CD29+, CD44+, CD90+, CD106+
(>70%), CD11b−, CD34−, CD45− (<5%) and adipogenic-,
chondrogenic-, and osteogenic-differentiation).
Using flow cytometry analysis (LSR II, Becton Dickinson, Hei-
delberg, Germany) we analyzed expression of two MSC-markers:
CD54 and CD90 and two negative-markers: CD34 and CD45 (Pit-
tenger et al., 1999; Wan et al., 2008; Hong et al., 2009). Briefly, cells
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were incubated with FITC-mouse monoclonal antibodies against
rat – CD34 (Santa Cruz; sc-7324), CD45 (BD; 550616), CD54 (BD;
554969), and CD90 Thy1/Thy1.1 (BD; 554894). For the control
served isotype-identical antibodies: Mouse IgG1 κ (BD; 550616)
and Mouse IgG2a κ (BD; 553456). Labeled cells were detected
on a LSR II (Becton Dickinson, Heidelberg, Germany) by collect-
ing 10.000 events using FACSDiva software (Becton Dickinson,
Heidelberg, Germany).
To proof evidence of multipotency of MSC we induced adi-
pogenic differentiation by the STEMPRO®Adipogenesis Differ-
entiation Kit (Gibco, Darmstadt, Germany). After 3 weeks, lipid
vacuoles within cells were detected by Oil-Red-O-staining in both
cell lines (Pittenger et al., 1999).
ENGINEERED TISSUE PRODUCTION FROMMSC (MSC-ET PRODUCTION)
For creating a MSC-ET, 2.5× 106 cultured MSC/ml, either (a)
sBM-MSC or (b) cBM-MSC, were mixed with matrigel, colla-
gen I, and serum containing media and were formed to rings
by casting into a circular structure as described (Leontyev et al.,
2013). Briefly, for preparing ET rings, 5× 106 cells suspended in
a total volume of 910µl M199 with 20% fetal calf serum and
penicillin/streptomycin were mixed 200µl matrigel (Becton Dick-
inson, Heidelberg, Germany), 500µl collagen I (5.5 mg/ml; Sigma,
Taufkirchen, Germany), 70µl 0.1 M NaOH (4%) and 320 double
concentrated M199 medium containing 20% horse serum and 4%
fetal calf serum, the pH was adjusted to 7.4 with HEPES (Zim-
mermann et al., 2006). The cell mixture was cast into a circular
ring-like structure of 10 mm diameter and 2 mm wall thickness
and allowed to solidify for 1 h. Thereafter, M199 media was added
carefully. After 24 h medium was changed. ET rings were then
allowed to grow in M199 media (supplemented with 10% horse
serum, 1% fetal calf serum, 2% chick embryo extract). After 5 days
of consolidation time MSC-ETs were electrically stimulated (1 Hz,
1 mV, and 0.1 mA) for further 6 days. In total the MSC-ETs were
cultivated for 2 weeks. We obtained six mesenchymal stem cell
Engineered Tissues (sMSC-ET) from sBM-MSC (passage 3) and
seven cMSC-ETs from cBM-MSC (passage 6).
CHRONIC MSC-ET IMPLANTATION IN THE RAT
Subsequently three of six sMSC-ETs and three of seven cMSC-ETs
were implanted around the beating heart of adult female Sprague
Dawley rats, which were obtained from University of Leipzig (the
remaining BM-ETs were used for pre-implantation histology, see
below). The ring-like MSC-ETs were implanted around the whole
heart, i.e., around the free wall of the left and right ventricles
in a circular manner below the valve plane. Rats were housed
in controlled facility with 12:12 h light/dark cycle with standard
laboratory diet.
In animals undergoing surgery: rats were anesthetized by com-
bined intramuscular application of fentanyl (0.005 mg/kg), mida-
zolam (2 mg/kg); medetomidin (0.15 mg/kg) and after intubation
isoflurane (1.5%), which was continued as inhalation anesthesia
(0.8–1% isoflurane). The thorax was opened by sternotomy. The
MSC-ET was directly implanted from the culture disk to the ani-
mal. MSC-ET rings were placed on the beating heart in the middle
of the left and right ventricle and actively fixed with four to five
(8/0 Prolene, Eticon) single-knot sutures.
All animals received immunosuppression for 30 days (day
80–110) with cyclosporin (5 mg/kg/day), methylprednisolone
(5 mg/kg/day), and azathioprine (2 mg/kg/day). After 1 month the
rat hearts were surgically excised and preserved for histological
analysis of the MSC-ETs in vivo.
HISTOLOGY
Cultivated in vitro MSC-ETs and rat hearts with the trans-
planted MSC-ETs were fixed in 4% buffered formaldehyde solu-
tion and embedded in paraffin for cutting 4µm thick sections,
and processed for standard Hematoxylin Eosin staining, and Azan-
novum, Elastica van Gieson and immunohistological staining. For
evaluating the amount of collagen fibers of the MSC-ET we used
the Azan-novum staining. Therefore the object slides were incu-
bated for 7 min in 0.1% Kernechtrubin solution, which stained
nuclei red. Subsequently collagen tissue was stained blue by 5 min
in aniline blue-Orange G. Existence of elastic fibers could be
shown by Elastica-van-Gieson-staining. Paraffin slides were put
in resorcin-fuchsin for 15 min and elastic fibers turned into a dark
purple. Nucleoli were stained brown by incubating for 5 min in
Weigert’s Hematoxylin.
IMMUNOHISTOCHEMISTRY
After a 10 min rinsing step in TBS, 4µm paraffin sections were
immersed in 0.01 M sodium citrate buffer (pH 6.0) and cooked
in a microwave for 30 min at 600 W. The endogenous peroxidase
activity was inhibited by incubating for 10 min in a solution con-
sisting of 60% methanol, 40% TBS, and 0,3% hydrogen peroxide.
Microscopic slides were blocked with 2% BSA for 1 h and afterward
they were incubated with 1:100 diluted rabbit polyclonal anti-von
Willebrand Factor (Ab6994, Abcam, Cambridge, UK) overnight at
4˚C. Subsequently, the samples were incubated with a secondary
anti-rabbit peroxidize-conjugated antibody (1:200) for 1 h at room
temperature. Von Willebrand Factor positive vessels were visual-
ized by staining them red with the chromogen AEC for 20 min
at room temperature and nuclei were counterstained by Mayer’s
hematoxylin.
For Cx40, Cx43, Cx45, CD90, CD20, CD3, CD45, and ki-
67 we used a polyclonal Cx40 antibody (AB1726, Millipore,
Schwalbach, Germany), a polyclonal rabbit anti-rat Cx43 anti-
body (C6219, Sigma, Taufkirchen, Germany), a rabbit anti-Cx45
antibody (AB1742, Chemicon, Temecula, CA, USA), a mouse
monoclonal CD90 antibody (ab225, Abcam, Cambridge, UK), a
goat polyclonal anti-CD20 antibody (Sc-7735, Santa Cruz, CA,
USA), a mouse monoclonal anti-CD45 antibody (Sc-53047, Santa
Cruz, CA, USA), a goat polyclonal anti-CD3-ε antibody (Sc-1127,
Santa Cruz, CA, USA), and a goat antibody against ki-67 (Sc7846,
SantaCruz, CA, USA). The immunofluorescence protocols varied
with regard to permeabilization and blocking. For each staining
protocol exposure times and antibody dilutions were tested and
optimized separately prior to the final experiments. The speci-
ficity of immunostaining for Cx40, Cx43, Cx45 was tested prior
to these experiments using transfected HeLa cells as described
(Hagen et al., 2009).
For Cx40 staining, the paraffin-fixed sections were permeabi-
lized for 15 min in a TBS solution with 0.1% Trypsin and 0.1%
CaCl2 (pH 7.8). For Cx43 labeling slides were put in sodium
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citrate buffer (pH 6.0) and cooked in a microwave for 30 min at
600 W. The Cx45 and CD90 slides were permeabilized for 30 min
in 1% Triton in PBS and blocked for further 60 min in 2% BSA in
PBS. Cx40 and Cx43 slides were blocked for 60 min in 2% BSA in
TBS. Afterward the slides were incubated with anti-Cx40 (1:100),
anti-Cx43 (1:2000), anti-Cx45 (1:100), anti-CD90 (1:100), or anti-
ki-67 (1:100) overnight at 4˚C. Next, the slides were incubated with
the appropriate Alexa Flour 488 or Alexa Flour 555 conjugated sec-
ondary antibodies (1:250) (Sigma, Taufkirchen, Germany) at room
temperature for 1 h. Background autofluorescence was inhibited
immersing for 1 min in 0.1% Chicago Blue in TBS. Nuclei were
stained for 1 min with DAPI in TBS.
For histomorphometric investigations single slides were taken
and the total field area for 10 randomly selected fields was exam-
ined. The heart sections were analyzed by blinded observers by
using microscopy Zeiss Axioplan2 Microscope (Jena, Germany)
equipped with a digital microscope camera (AxioCam MRC5
Zeiss, Jena, Germany). Exposure times and intensity for taking
immunofluorescence pictures were adjusted for the series of pic-
tures. The digital images were analyzed using AxioVision 4.6 (Zeiss,
Jena, Germany).
STATISTICS
All data are given as MEANS± SEM of n experiments. The data
were statistically analyzed by ANOVA, and if ANOVA indicated
Table 1 | characteristics of the two groups of bone marrow derived
stem cells used in this study.
% sBM-MSC cBM-MSC
CD90 94±3 99±1
CD54 72±4 96±1
CD34 0±0 0±0
CD45 13±2 0±0
Adipocyte formation rate 10±1 22±0.3
The percentage of cells which was positive for a certain antigen (FACS analy-
sis; mesenchymal marker: CD90, CD54; hematopoietic markers: CD34, CD45)
is given as well as the percentage of MSC which could be transformed to
adipocytes. All values are given as means±SEM.
significance, by post hoc Tukey HSD or by a Chi-square test
as appropriate on a level of significance of 0.05 using SYSTAT
software (SYSTAT 11.0; Jandel Scientific, Erkrath, Germany).
RESULTS
FACS ANALYSIS AND ADIPOGENIC DIFFERENTIATION OF ADULT
MESENCHYMAL STEM CELLS PRIOR TO TISSUE ENGINEERING AND
TRANSPLANTATION
Bone marrow derived mesenchymal stem cells (passage 3) exhib-
ited an expression of the mesenchymal surface markers CD90 and
CD54, and to a lower extent for the hematopoietic marker CD45,
while they were negative for the second hematopoietic marker
CD34. In comparison the commercial cBM-MSC (passage 6) also
were positive for CD90 and CD54, but were negative for both
CD34 and CD45 (Table 1).
Both types of BM-MSC showed the ability of adipogenic differ-
entiation, which was somewhat higher in cBM-MSC. After 3 weeks
of incubation with adipogenic supplementation, 10± 0.93% of
the sBM-MSC and 21.69± 0.31% of the cBM-MSC developed
Oil-Red-O-positive lipid droplets (Table 1). Non-treated control
cultures did not show spontaneous adipogenic formations after
3 weeks of cultivation (not shown).
FORMATION OF MSC-ETS IN VITRO AND IN VIVO
The MSC-ETs (sMSC-ETs; cMSC-ETs) did not exhibit any con-
tractions. Histological analysis of in vitro MSC-ET after 14 days of
culture showed that both types of MSC-ET had a high amount of
collagen, no elastic fibers, only very few vessels, almost no myocytes
(defined as troponin I expressing cells), but considerable numbers
of Cx43 or CD90 positive cells (see Table 2; Figure 1). Under
in vitro conditions the MSC-ETs did not exhibit specific Cx45
but showed slight Cx40 staining (Figures 1C,D). After 30 days
of implantation, the collagen content and the percentage of cells
positive for the mesenchymal marker CD90 was reduced, while the
number of vessels was increased, and a new formation of elastic
fibers could be observed (Table 2).
Surprisingly, in one of the three cMSC-ET-transplanted rats the
heart was completely surrounded by a sarcoma originating from
the cMSC-ET, which nearly filled the whole thorax. This was not
observed with sMSC-ETs. This tumor showed highly interesting
features regarding the distribution and expression of gap junction
Table 2 | Characteristics of the engineered tissues (ET) made from the two groups of bone marrow derived stem cells used in this study.
% In vitro ET In vivo ET
sMSC-ET cMSC-ET sMSC-ET cMSC-ET
Troponin+ cells 0.3±0.1 0.3±0.2 0.5±0.2 0.1±0.05
Cx43+ cells 38±2 74±4# 57±9* 50±11*
CD90+ cells 38±14 77±5# 16±4* 16±7*
Vessels/mm2 4±1 20±8# 49±9* 39±2*#
Collagen 70±2 64±2 37±3* 28±9*
Elastic fibers 0 0 1.8±0.2* 0.9±0.15*
The percentage of cells which was positive for a certain antigen (CD90, Cx43, troponin I) is given as well as the number of vessels/mm2 and the percentage of the
area which was covered by collagen or elastic fibers. All values are given as means±SEM. Significance (in vivo vs. in vitro are indicated by an asterisk, significance
between sBM-ET and cBM-ET is marked by # (p<0.05).
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FIGURE 1 | Original immunohistological images from in vitro
MSC-ETs. (A) sMSC-ET and (B) cMSC-ET. Red: troponin I, green:
Cx43, blue: DAPI. In both types no cross striation for troponin I can
be seen. There are numerous cells expressing Cx43. However, Cx43
is mostly located intracellularly and is distributed irregularly. (C,D)
Show Cx40 and Cx45 staining in cMSC-ET. Note the slight
punctuate Cx40 staining [red; (C)] and the absence of a specific
(red) Cx45 staining (D).
proteins showing no intercellular gap junction protein expres-
sion at the border between heart and tumor, while the tumor
expressed connexins in its inner center (but see below). Such tumor
formation was not observed in any of the other rats.
MORPHOLOGY AND MACROSCOPIC ANATOMY OF THE SARCOMA
The measured diameter of the solid tumor was from minimum
3.28 mm to maximum 12.39 mm. In comparison, the heart exhib-
ited a size of 9.03 mm (diameter measured at the widest transverse
section) and 13.48 mm (at the longitudinal section). The solid
neoplasm was well bounded and of tubercular shape. The inter-
section was white-greyly colored and it showed various lesions as
indicated by bleedings and necrosis, which reminded to the typical
description of a sarcoma (Fletcher, 1992). Figures 2A,B show the
macroscopic aspect of this tumor.
PATHOLOGY
Regarding the growth and location of the tumor, it became obvi-
ous that the tumor was originating from the cMSC-ET. The ET
had been implanted around the rat heart and the growth direc-
tion of the neoplasm was from the ET to the heart with several
infiltrations of the cardiac tissue.
The picture of the HE-staining (Figure 2C) was characterized
by closely, side by side laying cells and sparsely surrounding colla-
gen. The cells exhibited atypical nuclei and atypical cytoplasm. The
pleomorphic cells showed different sizes and their shape was from
clumsily oval through to round and only a few spindle shaped.
Some nuclei were equipped with nucleoli, but an eminent major-
ity of them were oversized and had a vesicular appearance, which
resulted in hypochromatic staining. The type of growth differed
between undirected and storiform and a few septums made of
collagen tissue caused a knotty division. Many inflammatory infil-
trates, predominantly consisting of lymphocytes, were found at
the transition between the neoplasm and the heart, in particular, at
spots, where the tumor had infiltrated the cardiac tissue. Atypical,
polynuclear giant cells were not detected, as would be expected for
a malignant giant cell tumor of soft tissues (Guccion and Enzinger,
1972; Angervall et al., 1981). By HE-staining we did not find any
differentiation characteristics such as lipoblasts or osteoid forma-
tion, together with a high nucleus/plasma ratio, which implied,
that the tumor is probably an undifferentiated pleomorphic sar-
coma. A lymphoma could be excluded by the finding that the
tumor cells were negative for CD3, CD20, and CD45.
GRADING
Following the hypothesis of this tumor being a sarcoma, there
are two acknowledged grading systems for soft tissue sarcomas.
We used the FNCLCC-system (Fédération Nationale des Centre
de Lutte contre le cancer), because it correlates better with the
clinical prognosis than the NCI-System (National Cancer Insti-
tute) (Guillou et al., 1997). The FNCLCC-system is based on three
parameters: tumor differentiation, mitotic activity and necrosis,
whereas the grading depends crucial on the histological type.
According to the FNCLCC-system the tumor in this case exhib-
ited an undifferentiated pattern, which couldn’t clearly dedicated
to one special type (=score 3). Moreover, we found 41 mitoses
in 10 high-power fields (1 HPF= 0.1734 mm2), which also gives
a score value of 3. Less than 50% of the tumor tissue consisted
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FIGURE 2 | (A,B) Macroscopic pathology of the tumor (red arrows point to the heart, black arrows indicate the grayish tumor mass). (C) Shows the HE histology
(white arrows indicate mitosis; black arrows point to nucleoli).
of necrotic areas (=score 1), so that the total score was 7 (=7/8)
corresponding to a high grade malignant sarcoma (Guillou et al.,
1997; Deyrup and Weiss, 2006).
DISTRIBUTION OF THE CONNEXINS 40, 43, AND 45 IN THE SARCOMA
AND THE HEART TISSUE
Immunohistochemical investigations revealed that the tumor cells
in the middle of the tumor were positive for all three cardiac
connexins, i.e., connexin 40, 43, and 45. By comparing the flu-
orescence signals of the three connexins, we recognized that most
cells stained positive for Cx43,while a smaller percentage expressed
Cx45 and Cx40. All of the three connexins were uniformly located
in the cytoplasm of the sarcoma cells, while the plasma membrane
was almost free of an immunopositive connexin signal and there
was no accentuation of the connexins near the nucleus. In par-
ticular, there were no selective accumulations of the fluorescence
between adjacent cells at the cell–cell-borders, which implies that
functional gap junctions are less probable (Figure 3). In contrast,
in the heart we found the typical localization of connexins at the
plasma membrane with accentuation at the cell–cell contacts in
particular at the cellular poles (Figures 3B,D,F).
Regarding the connexin expression, the sarcoma cells in the
present tumor can be divided into two areas: the first is the sar-
coma itself and the second is the transition zone between cardiac
tissue and sarcoma including the infiltrative growing sarcoma cells
(Figure 3B). The vast majority of sarcoma cells in the middle
and outer area of the tumor are positive for the three connexins
(Figures 3A,C,E), while in close vicinity of the transition zone
the sarcoma cells lost their positive connexin signal (Cx43, Cx40,
Cx45), which indicated that the tumor cells at the border do not
express any of the cardiac connexins (Figures 3B,D,F). In the heart
Cx43 is most prominently expressed.
With regard to the question whether connexin expression and
tumor growth may be interrelated we also investigated the expres-
sion of Ki-67, a marker of cell proliferation. In the middle of
the tumor only 37± 2% of the cells were Ki-67 positive, while at
the tumor-heart border significantly (p= 0.0007) more cells were
Ki-67 positive, i.e., 51± 7% Ki-67+ cells. This was accompanied
by a significant reduction in positivity for all cardiac connex-
ins (p< 0.001) from 30± 6 to 2± 2% of the cells expressing
any of the three connexins (p< 0.001). It became obvious, that
cells which were positive for Ki-67 mostly were negative for Cx43,
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FIGURE 3 | Expression of the three cardiac connexins Cx43 (A,B), Cx45
(C,D), and Cx40 (E,F) (connexins are stained green). (A,C,E) Show the
expression within the middle of the tumor, while (B,D,F) demonstrate the
loss of connexin expression in the invading zone of the tumor close to the
heart and a regular distribution of connexins in the heart itself. The white
arrows indicate a vessel.
Cx40, or Cx45 (Figure 4). In particular, at the tumor-heart border,
where the tumor infiltrated the heart, there were nearly no cells
which showed immunopositivity for connexin (Figure 5). Quan-
titatively, in the middle of the tumor we found a clear statistical
relationship between expression of Ki-67 and the lack connexin
expression (Chi-square test: Cx43: p< 0.0001; Cx45: p< 0.03,
Cx40: p< 0.014) where those cells expressing Ki-67 co-expressed
significantly more rarely connexin (Figure 6A). At the tumor-heart
border all cells expressing Ki-67 were negative for Cx43 and Cx40,
and only 2% co-expressed Ki-67 and Cx45 (Figure 6B).
DISCUSSION
As a main finding we observed an inverse relationship between
the expression of connexins, i.e., Cx43, Cx40, or Cx45, and of cell
proliferation marker Ki-67 (which is not present in G0 phase).
Moreover, in those parts of the tumor which invaded the heart,
i.e., in the growth zone with highest Ki-67 expression, connexin
expression was nearly absent. These data are in favor of the
hypothesis that tumors cells are not communicating with their
surrounding normal tissue when they grow invasively. In the
present case the tumor did not express any of the typical cardiac
connexins at the tumor-heart border where infiltrative growth
was found. That could mean, that these tumor cells can not get
growth-inhibitory signals from the normal cells via GJIC, thus,
enabling invasive growth. This is similar to Mesnil et al. (1994)
who found in a coculture of tumorigenic and non-tumorigenic
rat liver epithelial cell lines that Cx43 was abundantly expressed
in non-tumorigenic cells and was absent in tumorigenic cells. The
zone lacking Cx43 indicated the boundary between tumorigenic
and non-tumorigenic cells, similar to our tumor-heart border
(Mesnil et al., 1994). The finding, that the sarcoma cells showed
connexins rather predominantly intracytoplasmic than in the
cytoplasmic membrane suggests that these connexins may not
represent functional intercellular channels. A similar expression
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FIGURE 4 | Co-staining of Ki-67 (green) and Cx43 (A), Cx45 (B)
and Cx40 (C) (connexins are stained red) in the inner part of the
tumour. In (D) an overview is shown at a lower magnification.
Besides cells negative for both antigens (green arrow), cells are
either positive for Ki-67 (orange arrow) or for Cx43 (red arrow). Only
few cells co-express Cx43 and Ki-67 (white arrow).
FIGURE 5 |Tumor-heart border [(A); red arrows mark the transition to the heart] and non-infiltrated normal heart tissue (B). Co-staining of Ki-67 (green),
Cx43 (red), and nuclei (blue).
pattern has been shown for Cx32 and Cx43 in colorectal adenoma
and even augmented in carcinoma (Kanczuga-Koda et al., 2010).
By this aberrant localization, despite the expression of connex-
ins in the tumor, the absence of detectable connexin signals in
the membrane of the sarcoma cells probably means that they
will not form functional gap junctions. This may lead to insuf-
ficient homologous GJIC within the tumor (Yamasaki et al.,
1995). Similarly, Kalimi et al. (1992) reported of a reduction
of homologous GJIC in v-raf- and v-raf/v-myc-transformed rat
liver epithelial cells and a loss of heterologous GJIC in v-raf/v-
myc-transformed cells by using scrape loading-dye transfer and
fluorescence-recovery-after-photobleaching (FRAP) assays.
The role of GJIC in tumors is not entirely clear: on the one
hand there are several tumors which do not express any con-
nexin, e.g., HeLa cells (King et al., 2000a), and while many tumor
promoting agents down regulate GJIC (Salameh and Dhein, 2005),
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FIGURE 6 | Quantitative analysis of the relationship between connexin
expression and the proliferation marker Ki-67 in the middle of the
tumor (A) and at the tumor-heart border (B).
and while tumor oncogenes like ras, src, raf, and mos have been
shown to downregulate GJIC (Trosko et al., 2004). On the other
hand there are also reports that suggest that connexins expressed
in tumor cells may support the process of extravasation, invasion,
and metastasis (Lin et al., 2002; Elzarrad et al., 2008). Regarding
our study, in the tumor cells in our observation connexins are
expressed. However, these connexins are obviously located pre-
dominantly if not solely intracellularly, so that they probably do
not form functional channels. However, there was an interesting
difference between the middle of the tumor and its invading bor-
der: while in the middle cells expressed connexins, they did not or
almost not at the border.
The lack of membranous connexins would support the idea that
the tumor cells do not communicate with the neighboring cells
and, thus, can not receive growth inhibition signals from them.
They are blind for the neighbor cells since they do not express
the same connexins. Consequently, they do not see them and thus
proliferate without inhibition. Although attractive, this view is
probably too unilateral. Other signals may come from secreted
growth inhibitors from other cells or from the microenvironment
(Trosko et al., 1993; Barcellos-Hoff and Brooks, 2001). Regarding
the role of connexins, we have to discriminate channel-related
functions from channel-independent functions.
Thus, although not membrane-bound, connexin proteins are
not functionless but can exert regulatory functions on growth
and differentiation: it was shown that the carboxy terminal of
Cx43 can associate with β-catenin. Thereby, Cx43 can regulate
the cytosolic concentration of β-catenin. A reduction in Cx43, or
phosphorylation at S262 by FGF-2, can increase the free cytosolic
β-catenin which then in turn can translocate to the nucleus where
it can activate TCF/LEF transcription factors and genes related to
proliferation (like cyclin D, c-myc, c-jun) (Ai et al., 2000; Hol-
nthoner et al., 2002; Doble and Woodgett, 2003). Furthermore
the β-catenin-pool is regulated by wnt-Frizzled-receptor-signaling
which reduces GSK3 activity. GSK3 constitutively phosphory-
lates β-catenin and thereby marks it for proteasomal degradation
(Holnthoner et al., 2002; Doble and Woodgett, 2003).
Besides β-catenin, the secreted cysteine-rich and heparin bind-
ing protein CCN3 can interact with the carboxy terminal of Cx43
thereby inhibiting cellular proliferation (Fu et al., 2004; Gellhaus
et al., 2004).
Among the abundant proteins which can interact with con-
nexin43, zonula-occludens protein-1 (ZO-1), a scaffolding pro-
tein, is among the best investigated. The binding of ZO-1 to
connexin43 also fixes its binding partner ZONAB (ZO-1 asso-
ciated nucleic acid binding protein) together with CDK4 at the
membrane and prevents from its translocation to the nucleus. If
ZONAB is released it can together with CDK4 contribute to G1/S-
transition (Giepmans and Moolenaar, 1998; Sourisseau et al.,
2006). However, the binding of ZO-1 to connexin seems to be
at least mostly related to membrane-bound connexin.
Taken together, besides acting as intercellular communication
channel there is growing evidence that Cx43 can serve as an anti-
proliferative nexus platform or binding “hub” for proteins which
regulate growth. By docking to Cx43, the free concentration of
these proteins is controlled. Depending on Cx43 concentration or
phosphorylation status the other proteins may be released from
the “hub” and translocate to the nucleus, where they can induce
gene transcription linked to proliferation. Accordingly, a close rela-
tionship between Cx43 and important growth controlling genes
was shown by Iacobas et al. (2005a,b).
This view is supported by our data showing that the increase
in intracellular connexin is negatively related to the proliferation
marker Ki-67.
Interestingly, the tumor data suggest that some factor in the
middle of the tumor seemed to inhibit the synthesized connexins
from being transported to the membrane. From the present data
it remains unclear whether the connexin found intracellularly was
monomeric or whether it was already oligomerized to connexons.
Thus, it remains speculative to conclude on which level of the gap
junction formation the process was arrested. However, it is tempt-
ing to speculate that an agent which would overcome this arrest
may restore GJIC and thereby growth control.
Another issue worth some discussion is the stem cell. The
observed sarcoma seemed to originate from the stem-cell-derived
ET, which would mean that BM-MSC of a low passage (in that case
sixth passage) were able to transform to a malignant tumor. While
some investigators found functional connexins in MSC (Valiunas
et al., 2004), other researchers reported that stem cells typically
have no functional gap junctional intercellular communication
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and, thus, their growth control is assumed to be realized via
secreted factors or other extracellular signals from their surround-
ing (Trosko et al., 2004). Accordingly, although the cells in our
ET expressed connexins, these were predominantly located intra-
cellularly. To become a tumor cell, it is necessary that a cell is
immortalized and that it starts proliferation. Stem cells are con-
sidered to be immortal cells, which are under a non-gap-junction
growth control, and according to the theory from Trosko et al.
(2004) the carcinogenic process in this case would mean that this
naturally immortal stem cell is prevented from mortalization or
terminal differentiation. We can only speculate which factors in
the present observation may have contributed, and besides scaf-
fold factors it may be factors from the matrigel material or other
factors yet unknown.
However, these observations finally may suggest that connex-
ins like Cx43 might be interesting pharmacological anti-tumor
targets. Drugs would need to re-establish the transfer of con-
nexins to the membrane and their integration so that functional
channels can be formed in those cells which express connexins
intracellularly. Other drugs could act by re-expressing connex-
ins and re-establishing GJIC. However, to achieve growth control
this approach would require that the connexins re-expressed or
re-integrated in the tumor are compatible with those of the sur-
rounding normal tissue. This will not be possible in every case and
may be problematic in particular for metastasis, since connexins
may have a supportive role in the process of invasion/metastasis
(Ito et al., 2000; Lin et al., 2002; Elzarrad et al., 2008). However,
in a tumor as in the observed case, the proliferative invasive parts
did not express connexins and re-establishing gap junctional inter-
cellular communication could bear the chance to achieve growth
control in these cells. There are some reports which show the prin-
ciple feasibility of this approach (Zhang et al., 1998; King et al.,
2000b; Momiyama et al., 2003).
LIMITATIONS
As a limitation, it must be taken into account that we only tested
for the three cardiac connexins, and not all 21 isoforms. However,
since we were interested in the question whether the tumor may
form gap junctions with the heart, these would have to contain the
cardiac isoforms. Moreover, it would be interesting but was tech-
nically not possible to know if these tumor cells were definitively
lacking any functional intercellular gap junction communication.
Because of the use of a conventional fluorescence microscopy the
optical section thickness could be variable. However, we used 4µm
thin sections.
Regarding the grading of the tumor and its entity, the previ-
ously described macroscopy of the tumor and the fact that the
EHT consisted of 100% mesenchymal stem cells, led us to the
assumption that it had to be a sarcoma originating from the MSC.
The following histological examinations underlined this and sug-
gested a pleomorphic sarcoma. However, since we did not inves-
tigate this by the use of detailed further immunohistochem-
istry, we cannot exclude the possibility, that it could also be a
dedifferentiated high grade pleomorphic sarcoma (i.e., pleomor-
phic leiomyosarcoma,pleomorphic rhabdomyosarcoma) (Dei Tos,
2006). Moreover, it remains unclear whether the malignant trans-
formation might be inborn to these cells or whether it might
be caused/initiated by the treatment of these cells during the
process of ET formation. However, this might be of less impor-
tance for the observation of lack of communication proteins
at the tumor-heart border, which is the focus of the Present
study.
CONCLUSION
Taken together, we conclude that a pleomorphic sarcoma in the
rat does not express connexins at the locations of invasive growth,
and that proliferative activity and connexin expression are nega-
tively correlated. Moreover, our data show that this type of tumor
does not express tissue-specific connexins at the tumor tissue bor-
der. In consequence, we would underline the theory of Kalimi
et al. (1992) that probably such a tumor does not get growth lim-
itation signals from the surrounding normal tissue, which might
lead to unlimited infiltrating growth. Regarding pharmacological
perspectives a review of the current literature (see above) shows
that re-establishing of GJIC may help to bring the cells under
growth control again, but on the other hand it may also facilitate
the metastatic process by enhancing the adhesivity of tumor cells
to, e.g., vascular endothelium.
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